ECSP088590A - Derivados de aminoácido multicíclicos y sus métodos de uso - Google Patents

Derivados de aminoácido multicíclicos y sus métodos de uso

Info

Publication number
ECSP088590A
ECSP088590A EC2008008590A ECSP088590A ECSP088590A EC SP088590 A ECSP088590 A EC SP088590A EC 2008008590 A EC2008008590 A EC 2008008590A EC SP088590 A ECSP088590 A EC SP088590A EC SP088590 A ECSP088590 A EC SP088590A
Authority
EC
Ecuador
Prior art keywords
methods
amino acid
acid derivatives
multicyclic
multicyclic amino
Prior art date
Application number
EC2008008590A
Other languages
English (en)
Inventor
Arokiasamy Devasagayaraj
Haihong Jin
Qingyun Liu
Brett Marinelli
Lakshama Samala
Zhi-Cai Shi
Ashok Tunoori
Ying Wang
Wenxue Wu
Chengmin Zhang
Haiming Zhang
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of ECSP088590A publication Critical patent/ECSP088590A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/44—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by unsaturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Furan Compounds (AREA)

Abstract

Se describen compuestos de las fórmulas I y II, así como composiciones que los contienen y sus métodos de uso para tratar, prevenir y controlar enfermedades y trastornos mediados por serotonina.
EC2008008590A 2005-12-29 2008-06-30 Derivados de aminoácido multicíclicos y sus métodos de uso ECSP088590A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75495505P 2005-12-29 2005-12-29

Publications (1)

Publication Number Publication Date
ECSP088590A true ECSP088590A (es) 2008-11-27

Family

ID=38327831

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008590A ECSP088590A (es) 2005-12-29 2008-06-30 Derivados de aminoácido multicíclicos y sus métodos de uso

Country Status (20)

Country Link
US (3) US7723345B2 (es)
EP (2) EP1984344B1 (es)
JP (1) JP5483883B2 (es)
KR (1) KR101360621B1 (es)
CN (2) CN101351451B (es)
AU (1) AU2006337137B2 (es)
BR (1) BRPI0620756B1 (es)
CA (1) CA2635531C (es)
DK (1) DK1984344T3 (es)
EA (1) EA019879B1 (es)
EC (1) ECSP088590A (es)
ES (2) ES2395392T3 (es)
IL (1) IL191998A (es)
NO (1) NO344848B1 (es)
NZ (1) NZ568946A (es)
PL (1) PL1984344T3 (es)
PT (1) PT1984344E (es)
UA (1) UA96936C2 (es)
WO (1) WO2007089335A2 (es)
ZA (1) ZA200805192B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
TWI335328B (en) 2003-07-14 2011-01-01 Arena Pharm Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related hereto
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
US8518950B2 (en) 2005-01-25 2013-08-27 Synta Pharmaceuticals Corp. 2-amido pyrazines for inflammation and immune related uses
US7855291B2 (en) * 2005-12-29 2010-12-21 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
US7897763B2 (en) * 2005-12-29 2011-03-01 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
EA019879B1 (ru) * 2005-12-29 2014-07-30 Лексикон Фармасьютикалз, Инк. Полициклические производные аминокислот, содержащая их фармацевтическая композиция и способ лечения, использующий эти производные
LT2848610T (lt) * 2006-11-15 2017-11-10 Ym Biosciences Australia Pty Ltd Kinazės aktyvumo inhibitoriai
UA99270C2 (en) * 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
GB0705400D0 (en) * 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
AU2008268409B2 (en) * 2007-06-26 2013-12-05 Lexicon Pharmaceuticals, Inc. Compositions comprising tryptophan hydroxylase inhibitors
US20090005381A1 (en) * 2007-06-26 2009-01-01 Philip Manton Brown Methods of treating serotonin-mediated diseases and disorders
KR20100046189A (ko) 2007-07-11 2010-05-06 렉시컨 파마슈티컬스 인코퍼레이티드 폐고혈압 및 관련 질환 및 장애의 치료를 위한 방법 및 조성물
WO2009014972A1 (en) * 2007-07-26 2009-01-29 Lexicon Pharmaceuticals, Inc. Methods of affecting gastrointestinal transit and gastric emptying, and compounds useful therein
AU2008293679B2 (en) * 2007-08-24 2013-09-12 Tersera Therapeutics Llc Methods of preparing 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds
US20100260772A1 (en) * 2007-09-28 2010-10-14 The Trustees Of Columbia University In The City Of New York Methods for treating or preventing diseases associated with low bone mass
TWI439457B (zh) * 2007-09-28 2014-06-01 Lexicon Pharmaceuticals Inc （ｓ）－２－胺基－３－（４－（２－胺基－６－（（ｒ）－１－（４－氯－２－（３－甲基－１ｈ－吡唑－１－基）苯基）－２，２，２－三氟乙氧）－嘧啶－４－基）苯基）丙酸乙酯之固體形式與其使用方法
TW200932729A (en) * 2007-10-08 2009-08-01 Lexicon Pharmaceuticals Inc Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-methoxybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid and methods of their use
KR20100115789A (ko) 2008-02-04 2010-10-28 머큐리 테라퓨틱스, 인코포레이티드 Ａｍｐｋ 조절자
US8759364B2 (en) * 2008-03-31 2014-06-24 The Trustees Of Columbia University In The City Of New York Methods of treating bone mass diseases
CN101591332B (zh) * 2008-05-30 2014-04-16 莱西肯医药有限公司 基于4-苯基-6-(2,2,2-三氟-1-苯基乙氧基)嘧啶的化合物及其应用方法
US20100022549A1 (en) * 2008-07-23 2010-01-28 The Scripps Research Institute Alpha-helix mimetic with functionalized pyridazine
GB0817207D0 (en) * 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB0817208D0 (en) * 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
JP2012504642A (ja) * 2008-10-03 2012-02-23 レクシコン ファーマシューティカルズ インコーポレイテッド トリプトファンヒドロキシラーゼ阻害剤、及びこれらの使用方法
WO2010047712A1 (en) * 2008-10-24 2010-04-29 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
WO2010062829A1 (en) * 2008-11-28 2010-06-03 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for treating osteoporosis
WO2010065333A1 (en) * 2008-12-01 2010-06-10 Lexicon Pharmaceuticals, Inc. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds for the treatment of osteoporosis
WO2011053977A1 (en) * 2009-11-02 2011-05-05 The Trustees Of Columbia University In The City Of New York Compounds and methods for inhibiting serotonin synthesis
JP2013510092A (ja) * 2009-11-05 2013-03-21 レクシコン ファーマシューティカルズ インコーポレイテッド がんの治療のためのトリプトファンヒドロキシラーゼ阻害剤
CA2780203A1 (en) 2009-11-19 2011-05-26 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
US20120077831A1 (en) * 2009-11-23 2012-03-29 Philip Manton Brown Methods and assays for the treatment of irritable bowel syndrome
WO2011063181A1 (en) 2009-11-23 2011-05-26 Lexicon Pharmaceuticals, Inc. Methods and assays for the treatment of irritable bowel syndrome
CA2789229A1 (en) 2010-02-10 2011-08-18 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for the treatment of metastatic bone disease
TWI513694B (zh) 2010-05-11 2015-12-21 Amgen Inc 抑制間變性淋巴瘤激酶的嘧啶化合物
EP2582666B1 (en) 2010-06-16 2014-08-13 Purdue Pharma L.P. Aryl substituted indoles and their use as blockers of sodium channels
MX2013003184A (es) 2010-09-22 2013-06-07 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo.
TW201245183A (en) * 2010-11-05 2012-11-16 Lexicon Pharmaceuticals Inc Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoic acid
GB201203793D0 (en) * 2012-03-05 2012-04-18 Ge Healthcare Ltd Imaging neural activity
US20130303763A1 (en) 2012-03-30 2013-11-14 Michael D. Gershon Methods and compositions for the treatment of necrotizing enterocolitis
WO2014195847A2 (en) 2013-06-03 2014-12-11 Actelion Pharmaceuticals Ltd Novel use of stable isotope labeled l-tryptophan
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
CN105745211B (zh) * 2013-11-19 2017-09-26 埃科特莱茵药品有限公司 作为色氨酸羟化酶的抑制剂的三环咪唑化合物
AR098436A1 (es) * 2013-11-19 2016-05-26 Actelion Pharmaceuticals Ltd Compuestos tricíclicos de piperidina
WO2015089137A1 (en) * 2013-12-11 2015-06-18 Karos Pharmaceuticals, Inc. Acylguanidines as tryptophan hydroxylase inhibitors
WO2015163435A1 (ja) 2014-04-24 2015-10-29 田辺三菱製薬株式会社 新規２－アミノ－ピリジン及び２－アミノ－ピリミジン誘導体及びその医薬用途
US10308648B2 (en) 2014-10-16 2019-06-04 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
LT3262028T (lt) 2014-12-17 2022-01-10 Pimco 2664 Limited N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamido ir n-(-4-hidroksi-4-metil-cikloheksil)-4-(2-piridil)-benzensulfonamido junginiai ir jų terapinis panaudojimas
WO2016109501A1 (en) * 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Amide compounds as tryptophan hydroxylase inhibitors
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
JP2016204314A (ja) * 2015-04-23 2016-12-08 国立研究開発法人理化学研究所 化合物及び４−ボロノフェニルアラニン誘導体の製造方法
EP3292127A1 (en) 2015-05-04 2018-03-14 Actelion Pharmaceuticals Ltd Tricyclic piperidine compounds
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
KR102087907B1 (ko) * 2017-08-24 2020-03-11 광주과학기술원 신규한 트립토판 수산화효소 저해제 및 이를 포함하는 약학적 조성물
AU2019280822A1 (en) 2018-06-06 2021-01-07 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH471146A (de) 1966-03-16 1969-04-15 Geigy Ag J R Verfahren zur Herstellung von neuen Morpholinderivaten
US4866181A (en) 1986-08-29 1989-09-12 Aldrich-Boranes, Inc. Process for producing optically active alcohols
US4916074A (en) 1986-10-30 1990-04-10 Chisso Corporation Process for producing optically active compounds
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DE69129843T2 (de) 1991-03-21 1999-03-11 Solutia Europe N.V./S.A., Bruessel/Bruxelles Verbessertes katalytisches Verfahren zur selektiven Alkylierung von aromatischen Kohlenwasserstoffen
DE4131924A1 (de) 1991-09-25 1993-07-08 Hoechst Ag Substituierte 4-alkoxypyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
NZ276633A (en) 1993-11-24 1998-04-27 Du Pont Merck Pharma Isoxazole and isoxazoline derivatives and pharmaceutical compositions thereof
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5543133A (en) 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
GB9518553D0 (en) 1995-09-11 1995-11-08 Fujisawa Pharmaceutical Co New urea derivatives processes for the preparation thereof and pharmaceutical composition comprising the same
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
ES2171768T3 (es) 1996-03-20 2002-09-16 Hoechst Ag Inhibidores de la resorcion osea y antagonistas de receptores de vitronectina.
US5958957A (en) 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
US7378506B2 (en) 1997-07-21 2008-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
AU8747198A (en) 1997-08-20 1999-03-08 Kyowa Medex Co., Ltd. Novel compound 2-amino-3-{2-(alpha -mannopyranosyl)indol-3-yl}propionic acid, process for preparing the same, and method for inspecting function of living body with the novel compoun
US6455550B1 (en) 1997-08-22 2002-09-24 Hoffmann-La Roche Inc. N-alkanoylphenylalanine derivatives
US6229011B1 (en) 1997-08-22 2001-05-08 Hoffman-La Roche Inc. N-aroylphenylalanine derivative VCAM-1 inhibitors
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
CN1303286A (zh) * 1998-03-27 2001-07-11 法玛西雅厄普约翰美国公司 卡麦角林在治疗多动腿综合征中的应用
US6423727B1 (en) 1998-04-23 2002-07-23 Novartis Ag Certain thiol inhibitors of endothelin-converting enzyme
WO2000019994A1 (en) 1998-10-02 2000-04-13 Board Of Trustees Of The University Of Illinois Estrogen receptor ligands
JP2000204085A (ja) 1998-11-13 2000-07-25 Nippon Bayer Agrochem Co Ltd イソチアゾ―ルカルボン酸誘導体および病害防除剤
NZ512339A (en) * 1998-12-16 2003-03-28 Bayer Ag New biphenyl and biphenyl-analogous compounds as integrin antagonists
US6677360B2 (en) 1998-12-16 2004-01-13 Bayer Aktiengesellschaft Biphenyl and biphenyl-analogous compounds as integrin antagonists
KR100649819B1 (ko) 1999-02-18 2007-02-28 에프. 호프만-라 로슈 아게 티오아미드 유도체
HUP0203338A2 (hu) 1999-04-13 2003-03-28 Abbott Gmbh & Co. Kg Integrin receptor ligandumok
US7045532B2 (en) * 1999-04-30 2006-05-16 Millennium Pharmaceuticals, Inc. ACE-2 modulating compounds and methods of use thereof
JP4156807B2 (ja) 1999-06-01 2008-09-24 エラン ファーマ インターナショナル，リミティド 小型ミル及びその方法
EP1065208A1 (en) 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituted purine derivatives as inhibitors of cell adhesion
JP3795305B2 (ja) 1999-07-19 2006-07-12 田辺製薬株式会社 医薬組成物
AU6903200A (en) 1999-08-16 2001-03-13 Merck & Co., Inc. Heterocycle amides as cell adhesion inhibitors
ATE364592T1 (de) 1999-09-24 2007-07-15 Genentech Inc Tyrosinderivate
ES2299436T3 (es) 1999-10-06 2008-06-01 ABBOTT GMBH & CO. KG Composicion que comprende un inhibidor de tnf-alfa y un antagonista de receptor de integrina alfavbeta3.
DE10028575A1 (de) 2000-06-14 2002-03-14 Basf Ag Integrinliganden
CA2387857A1 (en) 1999-10-27 2001-05-03 Sunol Molecular Corporation Tissue factor antagonists and methods of use thereof
EP1233013B1 (en) 1999-11-18 2007-02-28 Ajinomoto Co., Inc. Novel phenylalanine derivatives
US6388084B1 (en) 1999-12-06 2002-05-14 Hoffmann-La Roche Inc. 4-pyridinyl-n-acyl-l-phenylalanines
EA004673B1 (ru) 1999-12-28 2004-06-24 Пфайзер Продактс Инк. Непептидильные ингибиторы vla-4-зависимого связывания клеток, применяемые при лечении воспалительных, аутоимунных и респираторных заболеваний
EP1251730A4 (en) 2000-01-26 2004-10-20 Univ Kansas State PRODUCTION AND USE OF POLYMERS CROSSLINKED WITH TYROSINE CONTAINING PEPTIDES
FR2804427B1 (fr) 2000-01-27 2002-09-06 Rhodia Chimie Sa Procede de preparation de cetones alpha-halogenees
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
JP2004501204A (ja) 2000-06-28 2004-01-15 プラナ　バイオテクノロジー　リミティッド 神経毒オリゴマー
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
US7015216B2 (en) 2000-07-21 2006-03-21 Elan Pharmaceuticals, Inc. Heteroaryl-β-alanine derivatives as alpha 4 integrin inhibitors
AU2001278986A1 (en) 2000-07-21 2002-02-05 Elan Pharmaceuticals, Inc. 3-amino-2-(4-aminocarbonyloxy)phenyl-propionic acid derivatives as alpha-4- integrin inhibitors
ATE497385T1 (de) 2000-08-18 2011-02-15 Ajinomoto Kk Neue phenylalanin-derivate
DE10042655A1 (de) 2000-08-31 2002-03-14 Aventis Pharma Gmbh Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
JP4895067B2 (ja) 2000-09-29 2012-03-14 味の素株式会社 新規フェニルアラニン誘導体
DE10112768A1 (de) 2001-03-16 2002-09-19 Merck Patent Gmbh Phenylderivate 3
US7176199B2 (en) 2001-03-19 2007-02-13 Dainippon Pharmaceutical Co., Ltd. Aryl-substituted alicyclic compound and medical composition comprising the same
US7081460B2 (en) 2001-04-09 2006-07-25 Ortho-Mcneil Pharmaceutical, Inc. Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders
JP2005500829A (ja) 2001-05-29 2005-01-13 レキシコン・ジェネティクス・インコーポレーテッド 新規ヒト水酸化酵素及び該酵素をコードするポリヌクレオチド
US6976647B2 (en) 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
PT1392441E (pt) 2001-06-05 2008-09-30 Elan Pharma Int Ltd Sistema e método para trituração de materiais
US6951840B2 (en) 2001-08-31 2005-10-04 Eli Lilly And Company Lipoglycopeptide antibiotics
WO2003053926A1 (en) 2001-12-13 2003-07-03 Ajinomoto Co.,Inc. Novel phenylalanine derivative
US20030171368A1 (en) 2002-02-06 2003-09-11 Werner Seitz Pyrimidinonesulfamoylureas`
EP1477482B1 (en) 2002-02-20 2010-04-14 Ajinomoto Co., Inc. Novel phenylalanine derivative
ES2378146T3 (es) 2002-04-03 2012-04-09 Novartis Ag Derivados de 1,1-dioxo-1, 2,5-tiazolidina-3-ona sustituida como inhibidores de ptpasa 1B
AU2003235256A1 (en) 2002-04-19 2003-11-03 Kyowa Hakko Kogyo Co., Ltd. Phenylalanine derivative
TW200407310A (en) 2002-06-07 2004-05-16 Glaxo Group Ltd Compounds
GB0213122D0 (en) 2002-06-07 2002-07-17 Glaxo Group Ltd Compounds
DE10226921A1 (de) 2002-06-17 2003-12-24 Bayer Ag Antibakterielle Amid-Makrozyklen
DE10234422A1 (de) 2002-07-29 2004-02-12 Bayer Ag Antibakterielle Ester-Makrozyklen
US7122580B2 (en) 2002-08-09 2006-10-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds and methods to modulate coagulation
US20050260126A1 (en) 2002-08-30 2005-11-24 Yukitsuka Kudo Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein
US7713551B2 (en) 2002-09-11 2010-05-11 Elan Pharma International Ltd. Gel stabilized nanoparticulate active agent compositions
WO2004043349A2 (en) 2002-11-06 2004-05-27 Bristol-Myers Squibb Company Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
WO2004046091A2 (en) 2002-11-19 2004-06-03 Galderma Research & Development, S.N.C. Biaromatic compounds which activate ppar-gama type receptors, and use thereof in cosmetic or pharmaceutical compositions
AU2003297431A1 (en) * 2002-12-20 2004-07-22 Pharmacia Corporation Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
ITMI20022738A1 (it) 2002-12-23 2004-06-24 Zambon Spa Derivati ftalazinici inibitori della fosfodiesterasi 4.
AU2003294142A1 (en) 2002-12-24 2004-07-22 Astrazeneca Ab Therapeutic quinazoline derivatives
JPWO2004080943A1 (ja) 2003-03-11 2006-06-08 小野薬品工業株式会社 シンナミルアルコール誘導体化合物およびその化合物を有効成分として含有する薬剤
US20050187266A1 (en) 2003-04-15 2005-08-25 Pfizer Inc Alpha substituted carboxylic acids
US20050234066A1 (en) 2004-04-15 2005-10-20 Agouron Pharmaceuticals, Inc. Alpha substituted carboxylic acids
JP2006517918A (ja) 2003-04-21 2006-08-03 ウスタブ オルガニケ ケミエ ア ビオケミエ ア カデミエ ベド チェスケ レプブリキ （プリン−６−イル）アミノ酸およびその製造方法
EP1628666B1 (en) 2003-05-14 2015-09-23 NeuroGenetic Pharmaceuticals, Inc. Compouds and uses thereof in modulating amyloid beta
JP4638423B2 (ja) 2003-06-20 2011-02-23 ガルデルマ・リサーチ・アンド・デヴェロップメント ＰＰＡＲγタイプ受容体を調節する新規化合物および化粧品組成物または医薬品組成物へのその使用
US20050042177A1 (en) 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
US7501538B2 (en) 2003-08-08 2009-03-10 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions and methods of use
WO2005014533A2 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
JP2008502583A (ja) 2003-10-01 2008-01-31 バイエル・ヘルスケア・アクチェンゲゼルシャフト 抗細菌性アミド大員環
US7141596B2 (en) 2003-10-08 2006-11-28 Incyte Corporation Inhibitors of proteins that bind phosphorylated molecules
RU2367659C2 (ru) 2003-11-05 2009-09-20 Ф.Хоффманн-Ля Рош Аг Гетероарильные производные в качестве активаторов рецепторов, активируемых пролифераторами пероксисом (ppar)
DE10358824A1 (de) 2003-12-16 2005-07-21 Bayer Healthcare Ag Antibakterielle Makrozyklen mit substituiertem Biphenyl
EP1700850B1 (en) 2003-12-22 2015-07-15 Ajinomoto Co., Inc. Phenylalanine derivative
EP2133427B1 (en) 2004-01-14 2013-12-11 Ohio University Methods of producing peptides/proteins in plants and peptides/proteins produced thereby
JP2007126358A (ja) 2004-01-20 2007-05-24 Fujiyakuhin Co Ltd フェニルアラニン誘導体
ES2617062T3 (es) 2004-02-05 2017-06-15 The Ohio State University Research Foundation Péptidos VEGF quiméricos
WO2005077915A1 (en) 2004-02-10 2005-08-25 Janssen Pharmaceutica, N.V. Pyridazinones as antagonists of a4 integrins
EP1746985A4 (en) 2004-05-21 2010-08-11 Univ Duke METHOD FOR INCREASING THE EFFECT OF SEROTONINE RECOVERY INHIBITORS
US20070265345A1 (en) 2004-07-27 2007-11-15 Smithkline Beecham Corporation Novel Biphenyl Compounds And Their Use
WO2006021886A1 (en) * 2004-08-26 2006-03-02 Pfizer Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
EA019879B1 (ru) * 2005-12-29 2014-07-30 Лексикон Фармасьютикалз, Инк. Полициклические производные аминокислот, содержащая их фармацевтическая композиция и способ лечения, использующий эти производные
US7897763B2 (en) * 2005-12-29 2011-03-01 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
UA99270C2 (en) * 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
AU2008268409B2 (en) * 2007-06-26 2013-12-05 Lexicon Pharmaceuticals, Inc. Compositions comprising tryptophan hydroxylase inhibitors
KR20100046189A (ko) * 2007-07-11 2010-05-06 렉시컨 파마슈티컬스 인코퍼레이티드 폐고혈압 및 관련 질환 및 장애의 치료를 위한 방법 및 조성물
TWI439457B (zh) * 2007-09-28 2014-06-01 Lexicon Pharmaceuticals Inc （ｓ）－２－胺基－３－（４－（２－胺基－６－（（ｒ）－１－（４－氯－２－（３－甲基－１ｈ－吡唑－１－基）苯基）－２，２，２－三氟乙氧）－嘧啶－４－基）苯基）丙酸乙酯之固體形式與其使用方法
TW200932729A (en) * 2007-10-08 2009-08-01 Lexicon Pharmaceuticals Inc Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-2,2,2-trifluoro-1-(3'-methoxybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid and methods of their use

Also Published As

Publication number Publication date
US7723345B2 (en) 2010-05-25
IL191998A (en) 2015-01-29
CN101351451B (zh) 2013-02-20
US8629156B2 (en) 2014-01-14
US20070191370A1 (en) 2007-08-16
BRPI0620756A2 (pt) 2011-11-22
JP5483883B2 (ja) 2014-05-07
CN103265495A (zh) 2013-08-28
EP1984344A2 (en) 2008-10-29
NO20083324L (no) 2008-08-13
UA96936C2 (uk) 2011-12-26
EP2386547B1 (en) 2018-06-20
HK1124841A1 (en) 2009-07-24
EA019879B1 (ru) 2014-07-30
PT1984344E (pt) 2012-12-21
EA200870127A1 (ru) 2009-02-27
CN103265495B (zh) 2016-11-16
AU2006337137A1 (en) 2007-08-09
KR20080081159A (ko) 2008-09-08
US8063057B2 (en) 2011-11-22
IL191998A0 (en) 2009-02-11
CA2635531A1 (en) 2007-08-09
KR101360621B1 (ko) 2014-02-07
ES2395392T3 (es) 2013-02-12
WO2007089335A2 (en) 2007-08-09
ES2684821T3 (es) 2018-10-04
DK1984344T3 (da) 2013-01-14
US20120157484A1 (en) 2012-06-21
CA2635531C (en) 2014-06-17
JP2009522265A (ja) 2009-06-11
AU2006337137B2 (en) 2012-06-14
ZA200805192B (en) 2009-11-25
CN101351451A (zh) 2009-01-21
NO344848B1 (no) 2020-05-25
US20100280054A1 (en) 2010-11-04
PL1984344T3 (pl) 2013-03-29
WO2007089335A3 (en) 2007-10-11
BRPI0620756B1 (pt) 2021-06-01
NZ568946A (en) 2010-07-30
EP1984344B1 (en) 2012-09-26
EP2386547A1 (en) 2011-11-16

Similar Documents

Publication Publication Date Title
DOP2011000076A (es) Derivados de heteroaril amidas y su uso como activadores de glucoquinasa
UY28876A1 (es) Compuestos de morfolina sustituida y composiciones para el tratamiento de trastornos del sistema nervioso central
UY30732A1 (es) Compuestos para la modulacion de la actividad del c-fms y/o el c-kit y sus usos aplicables
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
UY30748A1 (es) Compuesto0s novedosos
ECSP055676A (es) Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia
ECSP077271A (es) Derivados de pirimidina
ECSP088099A (es) Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas
CU20070160A7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
ECSP077259A (es) Derivados de pirimidina
ECSP067025A (es) DERIVADOS DE TETRAAZABENZO [e] AZULENO Y SUS ANÁLOGOS
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
ECSP078052A (es) Nuevos derivados de la 2-azetidinona como inhibidores de la absorción del colesterol para el tratamiento de condiciones hiperlipidémicas
ECSP088288A (es) DERIVADOS DE 7-(2-AMINO-1-HIDROXI-ETIL)-4-HIDROXIBENZOTIAZOL-2(3H)-ONA COMO AGONISTAS DE LOS ADRENOCEPTORES ß2
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
NI200900052A (es) Heterocíclicos derivados de los inhibidores de metaloproteasa
UY29414A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
EA200870127A1 (ru) Полициклические производные аминокислот и способы их применения
CO6630193A2 (es) Inhibidores de la actividad de la proteína tirosina quinasa seleccionada
UY29607A1 (es) Compuestos quimicos
ECSP066536A (es) Derivados de acidos fenoxiaceticos utiles como agonistas dobles dereceptor activado por proliferador de peroxisoma
CR11584A (es) Derivados de oxindol sustituidos y uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina
UY29003A1 (es) Nuevos derivados de hidantoína, procesos para su preparación, composiciones farmacéuticas que los contienen y su uso en terapia
CR7961A (es) Compuestos de aminoheteroarilo como inhibidores de las proteinquinasas